Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice of Absorption-Type Merger of a Wholly-Owned Subsidiary, Renalys Pharma, Inc.
CONSOLIDATED FINANCIAL STATEMENTS(IFRS)(Non-Audited)(for the nine months ended September 30, 2025)
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2025 (IFRS)
Notice Concerning Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary
F. Hoffmann-La Roche Announces Third Quarter Sales 2025
Chugai and Rani Therapeutics Enter into a License Agreement for the Development and Commercialization of an Oral Formulation
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Supplementary Materials Consolidated Financial Statements for the six months ended June 30, 2025 (IFRS)
Chugai to Construct a New Laboratory Building "UKX" to Strengthen Manufacturing Process Development Capabilities and Advance Environmental Initiatives
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2025)
F. Hoffmann-La Roche Announces Half Year Results 2025
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the three months ended March 31, 2025)
Supplementary Materials Consolidated Financial Statements for the three months ended March 31, 2025 (IFRS)
F. Hoffmann-La Roche Announces First Quarter Sales 2025
(Corrections) Notice of Partial Correction to "Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan"
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Corporate Governance Report of CHUGAI PHARMACEUTICAL CO., LTD.
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Position and Policy Regarding Reduction of the Investment Unit